ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer

Q: How does OCRA curate its research paper database?

OCRA indexes peer-reviewed papers from PubMed and CrossRef, enriched with MeSH terms, author profiles, and citation metrics. Papers are categorized by cancer type, research method, and clinical relevance.

Q: Can I search papers by MeSH term or author?

Yes. Use the search bar to filter papers by MeSH term, author name, journal, keyword, or cancer type. Each paper includes linked MeSH terms and author profiles for further exploration.

Q: How current is the paper database?

The database is updated regularly through automated ingestion from PubMed and CrossRef. Most papers appear within days of their PubMed indexing date.

Denisse Castro-Eguiluz

doi:10.1080/21645515.2021.1893036

ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer

Denisse Castro-Eguiluz · 2021-04-01

Human papillomavirus (HPV) infection is a well-known cause of cervical cancer. Therapeutic cancer vaccines are part of the current therapeutic options for HPV-associated cancers. Axalimogen filolisbac (ADXS11-001) is an immunotherapy based on live attenuated

ADXS11-001 LM-LLO as specific immunotherapy in cervical cancer

Links

Journal

Institutions

Authors